INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS
- 1 October 2004
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 172 (4 Part 1), 1529-1532
- https://doi.org/10.1097/01.ju.0000137844.77524.97
Abstract
Purpose: There is evidence that botulinum toxin A (BTX-A) might have analgesic properties. However, the mechanisms by which BTX-A alters pain remain largely unexplored. In the bladder afferent nerve fibers contain calcitonin gene-related peptide (CGRP). In this study we investigated the effect of intravesical BTX-A administration on CGRP immunoreactivity and bladder hyperactivity in an acetic acid induced bladder pain model in rats. Materials and Methods: Experimental and control animals were catheterized and intravesically exposed to protamine sulfate (1 ml, 10 mg/ml), followed by BTX-A (1 ml, 25 U/ml) or saline, respectively. Three or 7 days after intravesical therapy continuous cystometrograms were performed using urethane anesthesia by filling the bladder (0.08 ml per minute) with saline, followed by 0.3% acetic acid. Bladder immunohistochemistry was used to detect CGRP. Results: The intercontraction interval (ICI) was decreased after acetic acid instillation (50.2% and 65.0%) in the control group at days 3 and 7, respectively. However, rats that received BTX-A showed a significantly decreased response (28.6% ICI decrease) to acetic acid instillation at day 7. This effect was not observed at day 3 (62.2% ICI decrease). Increased CGRP immunoreactivity was detected in the BTX treated group at day 7, which was not detected at day 3. Conclusions: Intravesical BTX administration blocked acetic acid induced bladder pain responses and inhibited CGRP release from afferent nerve terminals. These results support the clinical application of BTX-A for the treatment of interstitial cystitis and other types of visceral pain.Keywords
This publication has 19 references indexed in Scilit:
- A Focused Review on the Use of Botulinum Toxins for Neuropathic PainThe Clinical Journal of Pain, 2002
- THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTORJournal of Urology, 2001
- Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxinsToxicon, 1999
- A Method for the Measurement of [3H]-Glutamate Release from Cultured Dorsal Root Ganglion NeuronsBiochemical Society Transactions, 1998
- Botulinum toxin A for spasticity, muscle spasms, and rigidityNeurology, 1995
- Treatment of interstitial cystitis with intravesical heparinBritish Journal of Urology, 1994
- Interstitial Cystitis: Increased Sympathetic Innervation and Related Neuropeptide SynthesisJournal of Urology, 1992
- Epithelial Dysfunction in Nonbacterial Cystitis (Interstitial Cystitis)Journal of Urology, 1991
- Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Calcitonin gene-related peptide immunoreactivity in afferent neurons supplying the urinary tract: Combined retrograde tracing and immunohistochemistryNeuroscience, 1986